Premium
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS
Author(s) -
Tarantelli C.,
Lange M.,
Gaudio E.,
Cascione L.,
Spriano F.,
Kwee I.,
Arribas A.,
Rinaldi A.,
Jourdan T.,
Berthold M.,
Margheriti F.,
Gritti G.,
Rossi D.,
Stathis A.,
Liu N.,
Zucca E.,
Politz O.,
Bertoni F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.127_2630
Subject(s) - venetoclax , mantle cell lymphoma , cancer research , panobinostat , ibrutinib , bendamustine , medicine , lymphoma , pharmacology , chemistry , chronic lymphocytic leukemia , rituximab , immunology , leukemia , histone deacetylase , biochemistry , gene , histone